Outcomes of Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A Real-World Experience - PubMed
4 hours ago
- #urothelial cancer
- #consolidative surgery
- #EVP therapy
- EVP is used as frontline treatment for advanced urothelial cancer, and consolidative surgery may be offered after EVP, but surgical outcome data are limited.
- Retrospective study of 23 patients with invasive bladder or high-risk upper tract urothelial cancer who had consolidative surgery post-EVP between 2022-2025.
- No major intraoperative complications occurred; all surgical margins were negative. Pathologic downstaging was 59%, and complete pathologic response was 45%.
- Post-surgery, 64% of patients experienced complications (27% high-grade), with no perioperative mortality. Within a median 14-month follow-up, 5 patients recurred and 2 died.
- Early findings indicate consolidative surgery post-EVP is feasible and can yield substantial pathologic responses in selected patients with advanced urothelial carcinoma.